Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $4,412,600 | $3,953,600 | $4,338,400 | $8,075,300 |
| Dep. & Amort. | $482,900 | $421,000 | $341,400 | $286,200 |
| Deferred Tax | -$757,300 | -$837,800 | -$746,400 | -$147,100 |
| Stock-Based Comp. | $982,800 | $885,000 | $725,000 | $601,700 |
| Change in WC | -$618,300 | -$94,100 | -$243,300 | -$1,916,500 |
| Other Non-Cash | -$82,200 | $266,300 | $599,800 | $181,700 |
| Operating Cash Flow | $4,420,500 | $4,594,000 | $5,014,900 | $7,081,300 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$755,900 | -$926,400 | -$590,100 | -$551,900 |
| Net Acquisitions | -$16,500 | -$54,900 | -$230,300 | $551,900 |
| Inv. Purchases | -$16,617,400 | -$11,646,000 | -$7,487,900 | -$7,048,100 |
| Inv. Sales/Matur. | $15,027,300 | $9,442,200 | $5,550,500 | $2,215,300 |
| Other Inv. Act. | -$105,600 | $0 | -$1,026,800 | -$551,900 |
| Investing Cash Flow | -$2,468,100 | -$3,185,100 | -$3,784,600 | -$5,384,700 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $1,465,300 | $1,145,500 | $1,519,500 | $1,672,300 |
| Stock Repurch. | -$3,632,400 | -$2,935,600 | -$2,528,500 | -$2,678,100 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$33,400 | $0 | $0 | $0 |
| Financing Cash Flow | -$2,200,500 | -$1,790,100 | -$1,009,000 | -$1,005,800 |
| Forex Effect | -$700 | -$400 | $0 | $0 |
| Net Chg. in Cash | -$248,800 | -$381,600 | $221,300 | $690,800 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $2,737,800 | $3,119,400 | $2,898,100 | $2,207,300 |
| End Cash | $2,489,000 | $2,737,800 | $3,119,400 | $2,898,100 |
| Free Cash Flow | $3,664,600 | $3,667,600 | $4,424,800 | $6,529,400 |